Adaptive Biotechnologies (NASDAQ:ADPT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Adaptive Biotechnologies (NASDAQ:ADPT) released its quarterly earnings data on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12), FiscalAI reports. The firm had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%.

Adaptive Biotechnologies Stock Up 0.2%

Adaptive Biotechnologies stock traded up $0.04 during mid-day trading on Wednesday, hitting $22.56. 3,146,606 shares of the stock were exchanged, compared to its average volume of 2,314,234. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -68.36 and a beta of 2.07. Adaptive Biotechnologies has a 12 month low of $9.96 and a 12 month high of $23.15. The firm’s fifty day simple moving average is $18.88 and its two-hundred day simple moving average is $16.51.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Wednesday, July 15th. JPMorgan Chase & Co. dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, June 29th. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Insider Activity

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 5,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $19.00, for a total transaction of $95,000.00. Following the sale, the insider owned 411,775 shares of the company’s stock, valued at approximately $7,823,725. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,305,787 shares of company stock valued at $27,828,563. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ADPT. T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $51,000. Strive Financial Group LLC bought a new stake in Adaptive Biotechnologies in the fourth quarter worth approximately $52,000. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the first quarter valued at approximately $93,000. Persistent Asset Partners Ltd acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $109,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Adaptive Biotechnologies during the 3rd quarter worth approximately $133,000. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.